Valeant Pharmaceuticals International Inc. (VRX: Quote,VRX.TO: Quote) has agreed to acquire OraPharma, a specialty oral health company, from Water Street Healthcare Partners, a private equity firm focused exclusively on the health care industry. Total consideration is around $312 million and up to $114 million in potential contingent payments based on certain milestones, including revenue targets.
OraPharma's lead product is Arestin, a locally administered antibiotic for the treatment of periodontitis that utilizes an advanced controlled-release delivery system and is indicated for use in conjunction with scaling and root planing for the treatment of adult periodontitis. As of March 31, 2012, OraPharma's trailing 12-month net revenue was some $95 million with the business growing at a high single digit rate.
The transaction, which may close in June 2012, is expected to be accretive in 2012.
Click here to receive FREE breaking news email alerts for Valeant Pharmaceuticals International and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org